Baxter International Inc. announced that the company has submitted a biologics license application (BLA) to the FDA for the approval...
Fuzeon is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients who have received treatment with and failed on regimens containing at least one medicinal product from each of the following antiretroviral classes: protease inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside reverse transcriptase inhibitors, or who have intolerance to previous antiretroviral regimens (see section 5.1). In deciding on a new regimen for patients who have failed an antiretroviral regimen, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different medicinal products. Where available, resistance testing may be appropriate (see sections 4.4 and 5.1).
Gilead Sciences, Inc. presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase II/III CAPELLA trial
BD (Becton, Dickinson and Company) released findings from a survey conducted by The Harris Poll, between Nov. 14-16, 2022, among 872 U.S. women ages 18 to 64 years old, that indicate a significant gap in women's knowledge about the primary causes of cervical cancer as well as the most effective means of prevention.
Biogen Idec has announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as...
AbbVie announced positive top-line results from SELECT-GCA, a Phase III, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (Rinvoq; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA).
AbbVie announced positive results from the ongoing Phase IIb/III SELECT-SUNRISE clinical trial showing that at 12 weeks, all doses of...
Objectives: To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months.
AbbVie announced new patient-reported outcomes data from the ongoing Phase III SELECT-MONOTHERAPY trial evaluating ABT 494 (upadacitinib) (15 mg and...